CytomX Therapeutics (CTMX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on CytomX Therapeutics (CTMX) is Neutral.

The composite score behind that read is -0.15, weighing +0.19 of bullish evidence against -0.36 bearish.

CytomX Therapeutics last closed at $2.57, +4.05% on the session.

Against the IVW growth benchmark the position is +3.25% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

12 graded predictions for CTMX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks CytomX Therapeutics in the 21st percentile on return on equity, where 100 is best.

CytomX Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $538.21M.

StockMap tracks CytomX Therapeutics as the 172nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite CytomX Therapeutics ranks 281st of 381 in the group, against a group median of -0.08.